Liminatus Pharma, Inc. (LIMNW) income statement

LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30

$0.04+0.00 (0.00%)

Close on Oct 30, 2026Market cap $189.39MP/E –Yield –

Liminatus Pharma, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31
Research & Development	0.60	0.40	–	–	–	–	0	0.36	0.71	–
General & Administrative	0.78	0.70	0.88	0.70	1.12	0.26	0.17	0.19	0.20	–
Operating Expenses	1.38	1.10	0.88	0.70	1.12	0.26	0.17	0.54	0.91	–
Operating Income	-1.38	-1.10	-0.88	-0.70	-1.12	-0.26	-0.17	-0.54	-0.91	0.00
Interest Expense	0.02	0.02	0.02	0.02	0.06	0.12	0.11	0.09	0.08	–
Interest & Investment Income	–	–	0	0	0.02	0.05	0.04	0.03	0.03	–
Other Non-Operating Income	-0.03	-0.02	-7.28	-1.12	1.23	-0.06	-0.06	-0.06	-0.05	–
Net Income incl. Noncontrolling Interests	-1.41	-1.12	-8.17	-1.82	0.11	-0.33	-0.23	-0.60	-2.71	0.00
Net Income	-1.41	-1.12	-8.17	-1.82	0.11	-0.33	-0.23	-0.60	-0.96	-1.75
Net Income to Common	–	–	–	–	0.11	–	–	–	-0.96	–
EPS (Basic)(per share)	-0.03	-0.03	-0.30	-0.07	0.00	-0.02	–	-0.03	-0.05	0.0000
EPS (Diluted)(per share)	-0.03	-0.03	-0.30	-0.07	0.00	-0.02	–	-0.03	-0.05	0.0000
Shares Outstanding (Basic, Weighted)(shares)	48	36	27	27	23	18	18	18	18	18
Shares Outstanding (Diluted, Weighted)(shares)	48	36	27	27	23	18	18	18	18	18

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 70.0%

Financial strength

Current ratio: 1.12
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 99.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 630.02
Dividend yield: –